Why Is 10X GENOMICS INC A (TXG) Stock Up Today?

10X Genomics Inc A (TXG) rose 12.57% to $58.57 in morning trading as multiple analysts raised price targets on the stock. The upward movement follows updated guidance from the company and several upgrades from key brokerage firms. The stock is currently trading above its 52-week high of $52.22 amid renewed investor interest.

What Happened

Canaccord raised its price target for TXG to $60 from $50, citing growth in AI and biopharma applications. Piper Sandler also increased its price target to $47 from $42, while Citigroup and Morgan Stanley raised their respective targets to $50 and $40. These moves reflect a broader consensus among analysts that the company is positioned to benefit from long-term industry trends. In addition, 10X Genomics raised its full-year 2026 sales guidance to a range of $610 million to $630 million, slightly above the current estimate of $613.851 million. This guidance revision contributed to the positive momentum in the stock.

What The Data Shows

TXG has a market capitalization of $6.8 billion but remains unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -0.59 and a TTM revenue decline of 4.3%. The stock has a beta of 2.04, indicating higher volatility than the broader market. Recent insider transactions show five sales totaling $2.6 million in the last 90 days, with no buy activity. The CEO and a director have both sold shares in recent months. The stock is currently trading at a net margin of -12.2% and remains below breakeven on a fundamental basis.

What To Watch

Investors should monitor the company’s ability to meet its revised 2026 sales guidance and any further analyst coverage changes. The stock remains unprofitable, so earnings developments or shifts in market sentiment could influence its trajectory.